ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
62,995.21
-0.08%
S&P 500
5,214.08
0.51%
Dow Jones
39,387.76
0.85%
US Dollar vs Yen
155.6295
0.15%
Brent Oil
83.895
-0.07%
Registration Strip Icon for default 登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. BioLineRx Ltd (BLRX)

  7. BioLineRx Ltd (BLRX) ニュース

BLRX

BioLineRx (BLRX)

BioLineRx Ltd
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:BLRX
日付受信時刻ニュースソース見出しコード企業名
2024/05/0620 : 14Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
2024/04/1720 : 00PR Newswire (US)BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual MeetingNASDAQ:BLRXBioLineRx Ltd
2024/03/0421 : 47Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
2024/02/2821 : 08Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
2024/02/1621 : 07Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
2024/01/0814 : 15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:BLRXBioLineRx Ltd
2023/12/3006 : 20Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:BLRXBioLineRx Ltd
2023/12/3006 : 15Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:BLRXBioLineRx Ltd
2023/12/2121 : 05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
2023/12/1221 : 07Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
2023/11/2021 : 03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
2023/11/2020 : 25IH Market NewsMonday’s Wall Street Highlights: GM, Microsoft, Citigroup, Amazon, and moreNASDAQ:BLRXBioLineRx Ltd
2023/11/0120 : 43PR Newswire (Canada)BioLineRx a conclu un accord de licence exclusive pour le motixafortide en Asie, sous les conseils de MSQ VenturesNASDAQ:BLRXBioLineRx Ltd
2023/10/3122 : 00PR Newswire (US)BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. VenturesNASDAQ:BLRXBioLineRx Ltd
2023/10/3122 : 00PR Newswire (Canada)BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. VenturesNASDAQ:BLRXBioLineRx Ltd
2023/10/2703 : 18Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:BLRXBioLineRx Ltd
2023/10/1906 : 07AllPennyStocks.comNew Collaboration Could Revolutionize Treatment of Chronic Spinal Cord InjuriesNASDAQ:BLRXBioLineRx Ltd
2023/10/1220 : 14Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
2023/09/2820 : 11Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
2023/09/1120 : 07Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
2023/09/1120 : 00PR Newswire (US)BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple MyelomaNASDAQ:BLRXBioLineRx Ltd
2023/08/3020 : 16IH Market NewsWednesday’s Wall Street Highlights: Ambarella, Alphabet, Toyota, HP Inc, Vinfast, and moreNASDAQ:BLRXBioLineRx Ltd
2023/08/3020 : 15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
2023/08/3019 : 45Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
2023/08/0906 : 25Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
2023/07/1720 : 10Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
2023/06/2405 : 17Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:BLRXBioLineRx Ltd
2023/05/2420 : 07Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:BLRXBioLineRx Ltd
2023/04/2520 : 08Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:BLRXBioLineRx Ltd
2023/04/1800 : 09Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:BLRXBioLineRx Ltd
 Showing the most relevant articles for your search:NASDAQ:BLRX

最近閲覧した銘柄

NASDAQ
MSFT
Microsoft
AMEX
XLV
Health Care Select Sector
COIN
BTCUSD
Bitcoin
COIN
ETHUSD
Ethereum
NYSE
MRK
Merck
NASDAQ
AMZN
Amazon.com
NASDAQ
TSLA
Tesla
NYSE
AXP
American Express
COIN
SOLUSD
Solana
FX
USDGBP
US Dollar vs Sterling
USI
USTECH100
US Tech 100
NYSE
CVX
Chevron
NASDAQ
AAPL
Apple
NYSE
JPM
JP Morgan Chase
AMEX
XLF
Financial Select Sector
USOTC
BNPQY
BNP Paribas (QX)
Delayed Upgrade Clock
ADVFN Logo

日本
会社情報
ビジネス
人気
アプリを入手

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有